Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 10 May 1991:
Vol. 252. no. 5007, pp. 854 - 856
DOI: 10.1126/science.1851332
Prev | Table of Contents | Next

Articles

Science, Vol 252, Issue 5007, 854-856
Copyright © 1991 by American Association for the Advancement of Science

articles

Experimental therapy of human glioma by means of a genetically engineered virus mutant

RL Martuza, A Malick, JM Markert, KL Ruffner, and DM Coen

Molecular Neurogenetics Laboratory, Harvard Medical School, Massachusetts General Hospital-East, Charlestown 02129.

Malignant gliomas are the most common malignant brain tumors and are almost always fatal. A thymidine kinase-negative mutant of herpes simplex virus-1 (dlsptk) that is attenuated for neurovirulence was tested as a possible treatment for gliomas. In cell culture, dlsptk killed two long-term human glioma lines and three short-term human glioma cell populations. In nude mice with implanted subcutaneous and subrenal U87 human gliomas, intraneoplastic inoculation of dlsptk caused growth inhibition. In nude mice with intracranial U87 gliomas, intraneoplastic inoculation of dlsptk prolonged survival. Genetically engineered viruses such as dlsptk merit further evaluation as novel antineoplastic agents.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Coronavirus Genetically Redirected to the Epidermal Growth Factor Receptor Exhibits Effective Antitumor Activity against a Malignant Glioblastoma.
M. H. Verheije, M. L. M. Lamfers, T. Wurdinger, G. C. M. Grinwis, W. R. Gerritsen, V. W. van Beusechem, and P. J. M. Rottier (2009)
J. Virol. 83, 7507-7516
   Abstract »    Full Text »    PDF »
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.
L. Menotti, G. Nicoletti, V. Gatta, S. Croci, L. Landuzzi, C. De Giovanni, P. Nanni, P.-L. Lollini, and G. Campadelli-Fiume (2009)
PNAS 106, 9039-9044
   Abstract »    Full Text »    PDF »
Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.
J. Jin, H. Liu, C. Yang, G. Li, X. Liu, Q. Qian, and W. Qian (2009)
Mol. Cancer Ther. 8, 1387-1397
   Abstract »    Full Text »    PDF »
Efficacy of Systemically Administered Oncolytic Vaccinia Virotherapy for Malignant Gliomas Is Enhanced by Combination Therapy with Rapamycin or Cyclophosphamide.
X. Q. Lun, J.-H. Jang, N. Tang, H. Deng, R. Head, J. C. Bell, D. F. Stojdl, C. L. Nutt, D. L. Senger, P. A. Forsyth, et al. (2009)
Clin. Cancer Res. 15, 2777-2788
   Abstract »    Full Text »    PDF »
In vivo gene delivery by embryonic-stem-cell-derived astrocytes for malignant gliomas.
M. Uzzaman, G. Keller, and I. M. Germano (2009)
Neuro-oncol 11, 102-108
   Abstract »    Full Text »    PDF »
Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2.
L. Menotti, A. Cerretani, H. Hengel, and G. Campadelli-Fiume (2008)
J. Virol. 82, 10153-10161
   Abstract »    Full Text »    PDF »
Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer.
S.-F. Lin, S. P. Gao, D. L. Price, S. Li, T.-C. Chou, P. Singh, Y.-Y. Huang, Y. Fong, and R. J. Wong (2008)
Clin. Cancer Res. 14, 1519-1528
   Abstract »    Full Text »    PDF »
Herpes Simplex Virus Type 1 Preferentially Targets Human Colon Carcinoma: Role of Extracellular Matrix.
D. Kolodkin-Gal, G. Zamir, Y. Edden, E. Pikarsky, A. Pikarsky, H. Haim, Y. S. Haviv, and A. Panet (2008)
J. Virol. 82, 999-1010
   Abstract »    Full Text »    PDF »
Systemic Therapy of Spontaneous Prostate Cancer in Transgenic Mice with Oncolytic Herpes Simplex Viruses.
S. Varghese, S. D. Rabkin, G. P. Nielsen, U. MacGarvey, R. Liu, and R. L. Martuza (2007)
Cancer Res. 67, 9371-9379
   Abstract »    Full Text »    PDF »
Depletion of Peripheral Macrophages and Brain Microglia Increases Brain Tumor Titers of Oncolytic Viruses.
G. Fulci, N. Dmitrieva, D. Gianni, E. J. Fontana, X. Pan, Y. Lu, C. S. Kaufman, B. Kaur, S. E. Lawler, R. J. Lee, et al. (2007)
Cancer Res. 67, 9398-9406
   Abstract »    Full Text »    PDF »
Enhancing Radiotherapy With Genetically Engineered Viruses.
S. J. Advani, R. R. Weichselbaum, and S. J. Chmura (2007)
J. Clin. Oncol. 25, 4090-4095
   Abstract »    Full Text »    PDF »
Nectin-1 Is a Marker of Thyroid Cancer Sensitivity to Herpes Oncolytic Therapy.
Y.-Y. Huang, Z. Yu, S.-F. Lin, S. Li, Y. Fong, and R. J. Wong (2007)
J. Clin. Endocrinol. Metab. 92, 1965-1970
   Abstract »    Full Text »    PDF »
Antitumor Activity of an Oncolytic Adenovirus-Delivered Oncogene Small Interfering RNA.
Y.-A. Zhang, J. Nemunaitis, S. K. Samuel, P. Chen, Y. Shen, and A. W. Tong (2006)
Cancer Res. 66, 9736-9743
   Abstract »    Full Text »    PDF »
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.
G. Fulci, L. Breymann, D. Gianni, K. Kurozomi, S. S. Rhee, J. Yu, B. Kaur, D. N. Louis, R. Weissleder, M. A. Caligiuri, et al. (2006)
PNAS 103, 12873-12878
   Abstract »    Full Text »    PDF »
Serial Passage through Human Glioma Xenografts Selects for a {Delta}{gamma}134.5 Herpes Simplex Virus Type 1 Mutant That Exhibits Decreased Neurotoxicity and Prolongs Survival of Mice with Experimental Brain Tumors..
A. C. Shah, K. H. Price, J. N. Parker, S. L. Samuel, S. Meleth, K. A. Cassady, G. Yancey Gillespie, R. J. Whitley, and J. M. Markert (2006)
J. Virol. 80, 7308-7315
   Abstract »    Full Text »    PDF »
Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer.
H. Kimata, T. Imai, T. Kikumori, O. Teshigahara, T. Nagasaka, F. Goshima, Y. Nishiyama, and A. Nakao (2006)
Ann. Surg. Oncol. 13, 1078-1084
   Abstract »    Full Text »    PDF »
Effective treatment of pancreatic cancer xenografts with a conditionally replicating virus derived from type 2 herpes simplex virus..
X. Fu, L. Tao, M. Li, W. E. Fisher, and X. Zhang (2006)
Clin. Cancer Res. 12, 3152-3157
   Abstract »    Full Text »    PDF »
Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus..
H. Ito, H. Aoki, F. Kuhnel, Y. Kondo, S. Kubicka, T. Wirth, E. Iwado, A. Iwamaru, K. Fujiwara, K. R. Hess, et al. (2006)
J Natl Cancer Inst 98, 625-636
   Abstract »    Full Text »    PDF »
Targeted Therapy for Glioblastoma Multiforme Neoplastic Meningitis with Intrathecal Delivery of an Oncolytic Recombinant Poliovirus.
H. Ochiai, S. A. Campbell, G. E. Archer, T. A. Chewning, E. Dragunsky, A. Ivanov, M. Gromeier, and J. H. Sampson (2006)
Clin. Cancer Res. 12, 1349-1354
   Abstract »    Full Text »    PDF »
Myxoma Virus Is a Novel Oncolytic Virus with Significant Antitumor Activity against Experimental Human Gliomas.
X. Lun, W. Yang, T. Alain, Z.-Q. Shi, H. Muzik, J. W. Barrett, G. McFadden, J. Bell, M. G. Hamilton, D. L. Senger, et al. (2005)
Cancer Res. 65, 9982-9990
   Abstract »    Full Text »    PDF »
Ionizing Radiation Activates Late Herpes Simplex Virus 1 Promoters via the p38 Pathway in Tumors Treated with Oncolytic Viruses.
J. J. Mezhir, S. J. Advani, K. D. Smith, T. E. Darga, A. P.W. Poon, H. Schmidt, M. C. Posner, B. Roizman, and R. R. Weichselbaum (2005)
Cancer Res. 65, 9479-9484
   Abstract »    Full Text »    PDF »
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.
E. K. Hellums, J. M. Markert, J. N. Parker, B. He, B. Perbal, B. Roizman, R. J. Whitley, C. P. Langford, S. Bharara, and G. Y. Gillespie (2005)
Neuro-oncol 7, 213-224
   Abstract »    PDF »
Inhibition of DNA Repair by a Herpes Simplex Virus Vector Enhances the Radiosensitivity of Human Glioblastoma Cells.
C. G. Hadjipanayis and N. A. DeLuca (2005)
Cancer Res. 65, 5310-5316
   Abstract »    Full Text »    PDF »
Construction of a Minimal HIV-1 Variant that Selectively Replicates in Leukemic Derived T-Cell Lines: Towards a New Virotherapy Approach.
R. E. Jeeninga, B. Jan, B. van der Linden, H. van den Berg, and B. Berkhout (2005)
Cancer Res. 65, 3347-3355
   Abstract »    Full Text »    PDF »
Oncolytic Viral Therapeutics Based on Herpes Simplex Virus Type I.
E. A. Chiocca (2005)
Am. Assoc. Cancer Res. Educ. Book 2005, 139-140
   Full Text »    PDF »
Next Generation CRAds for Virotherapy of Cancer.
D. T. Curiel (2005)
Am. Assoc. Cancer Res. Educ. Book 2005, 141-144
   Full Text »    PDF »
Treatment of Intracerebral Neoplasia and Neoplastic Meningitis with Regional Delivery of Oncolytic Recombinant Poliovirus.
H. Ochiai, S. A. Moore, G. E. Archer, T. Okamura, T. A. Chewning, J. R. Marks, J. H. Sampson, and M. Gromeier (2004)
Clin. Cancer Res. 10, 4831-4838
   Abstract »    Full Text »    PDF »
Poliovirus receptor CD155-targeted oncolysis of glioma.
M. K. Merrill, G. Bernhardt, J. H. Sampson, C. J. Wikstrand, D. D. Bigner, and M. Gromeier (2004)
Neuro-oncol 6, 208-217
   Abstract »    PDF »
Selectivity of an Oncolytic Herpes Simplex Virus for Cells Expressing the DF3/MUC1 Antigen.
H. Kasuya, T. M. Pawlik, J. T. Mullen, J. M. Donahue, H. Nakamura, S. Chandrasekhar, H. Kawasaki, E. Choi, and K. K. Tanabe (2004)
Cancer Res. 64, 2561-2567
   Abstract »    Full Text »    PDF »
Viral Oncolysis for Malignant Liver Tumors.
J. T. Mullen and K. K. Tanabe (2003)
Ann. Surg. Oncol. 10, 596-605
   Abstract »    Full Text »    PDF »
Effective Therapy of Metastatic Ovarian Cancer with an Oncolytic Herpes Simplex Virus Incorporating Two Membrane Fusion Mechanisms.
M. Nakamori, X. Fu, F. Meng, A. Jin, L. Tao, R. C. Bast Jr., and X. Zhang (2003)
Clin. Cancer Res. 9, 2727-2733
   Abstract »    Full Text »    PDF »
Reovirus Prolongs Survival and Reduces the Frequency of Spinal and Leptomeningeal Metastases from Medulloblastoma.
W. Q. Yang, D. Senger, H. Muzik, Z. Q. Shi, D. Johnson, P. M. A. Brasher, N. B. Rewcastle, M. Hamilton, J. Rutka, J. Wolff, et al. (2003)
Cancer Res. 63, 3162-3172
   Abstract »    Full Text »    PDF »
Systemic Reovirus Therapy of Metastatic Cancer in Immune-competent Mice.
K. Hirasawa, S. G. Nishikawa, K. L. Norman, M. C. Coffey, B. G. Thompson, C.-S. Yoon, D. M. Waisman, and P. W. K. Lee (2003)
Cancer Res. 63, 348-353
   Abstract »    Full Text »    PDF »
Hepatic Arterial Infusion of a Replication-selective Oncolytic Adenovirus (dl1520): Phase II Viral, Immunologic, and Clinical Endpoints.
T. Reid, E. Galanis, J. Abbruzzese, D. Sze, L. M. Wein, J. Andrews, B. Randlev, C. Heise, M. Uprichard, M. Hatfield, et al. (2002)
Cancer Res. 62, 6070-6079
   Abstract »    Full Text »    PDF »
Viral Oncolysis.
J. T. Mullen and K. K. Tanabe (2002)
Oncologist 7, 106-119
   Abstract »    Full Text »    PDF »
Cytolytic viruses as potential anti-cancer agents.
C. J. A. Ring (2002)
J. Gen. Virol. 83, 491-502
   Abstract »    Full Text »    PDF »
Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes.
J. A. McCart, J. M. Ward, J. Lee, Y. Hu, H. R. Alexander, S. K. Libutti, B. Moss, and D. L. Bartlett (2001)
Cancer Res. 61, 8751-8757
   Abstract »    Full Text »    PDF »
Systemic therapy of myeloma xenografts by an attenuated measles virus.
K.-W. Peng, G. J. Ahmann, L. Pham, P. R. Greipp, R. Cattaneo, and S. J. Russell (2001)
Blood 98, 2002-2007
   Abstract »    Full Text »    PDF »
Multimodality Therapy with a Replication-conditional Herpes Simplex Virus 1 Mutant that Expresses Yeast Cytosine Deaminase for Intratumoral Conversion of 5-Fluorocytosine to 5-Fluorouracil.
H. Nakamura, J. T. Mullen, S. Chandrasekhar, T. M. Pawlik, S. S. Yoon, and K. K. Tanabe (2001)
Cancer Res. 61, 5447-5452
   Abstract »    Full Text »    PDF »
Viruses as Therapeutic Agents Against Malignant Disease of the Central Nervous System.
M. Gromeier (2001)
J Natl Cancer Inst 93, 889-890
   Full Text »    PDF »
Reovirus as an Oncolytic Agent Against Experimental Human Malignant Gliomas.
M. E. Wilcox, W. Yang, D. Senger, N. B. Rewcastle, D. G. Morris, P. M. A. Brasher, Z. Q. Shi, R. N. Johnston, S. Nishikawa, P. W. K. Lee, et al. (2001)
J Natl Cancer Inst 93, 903-912
   Abstract »    Full Text »    PDF »
A Herpes Simplex Virus Type 1 {gamma}34.5 Second-Site Suppressor Mutant That Exhibits Enhanced Growth in Cultured Glioblastoma Cells Is Severely Attenuated in Animals.
I. Mohr, D. Sternberg, S. Ward, D. Leib, M. Mulvey, and Y. Gluzman (2001)
J. Virol. 75, 5189-5196
   Abstract »    Full Text »
Identification of the Transcriptional Regulatory Sequences of Human Calponin Promoter and Their Use in Targeting a Conditionally Replicating Herpes Vector to Malignant Human Soft Tissue and Bone Tumors.
H. Yamamura, M. Hashio, M. Noguchi, Y. Sugenoya, M. Osakada, N. Hirano, Y. Sasaki, T. Yoden, N. Awata, N. Araki, et al. (2001)
Cancer Res. 61, 3969-3977
   Abstract »    Full Text »
Direct Stimulation of Apoptotic Signaling by Soluble Apo2L/Tumor Necrosis Factor-related Apoptosis-inducing Ligand Leads to Selective Killing of Glioma Cells.
I. F. Pollack, M. Erff, and A. Ashkenazi (2001)
Clin. Cancer Res. 7, 1362-1369
   Abstract »    Full Text »
Potential of gene therapy for brain tumors.
P. Y.P. Lam and X. O. Breakefield (2001)
Hum. Mol. Genet. 10, 777-787
   Abstract »    Full Text »    PDF »
Positron Emission Tomography-based Imaging of Transgene Expression Mediated by Replication-conditional, Oncolytic Herpes Simplex Virus Type 1 Mutant Vectors in Vivo.
A. Jacobs, J. G. Tjuvajev, M. Dubrovin, T. Akhurst, J. Balatoni, B. Beattie, R. Joshi, R. Finn, S. M. Larson, U. Herrlinger, et al. (2001)
Cancer Res. 61, 2983-2995
   Abstract »    Full Text »
Expression of p57KIP2 Potently Blocks the Growth of Human Astrocytomas and Induces Cell Senescence.
A. Tsugu, K. Sakai, P. B. Dirks, S. Jung, R. Weksberg, Y.-L. Fei, S. Mondal, S. Ivanchuk, C. Ackerley, P. A. Hamel, et al. (2000)
Am. J. Pathol. 157, 919-932
   Abstract »    Full Text »    PDF »
Oncolytic Herpes Simplex Virus-1 Lacking ICP34.5 Induces p53-independent Death and Is Efficacious against Chemotherapy-resistant Ovarian Cancer.
G. Coukos, A. Makrigiannakis, E. H. Kang, S. C. Rubin, S. M. Albelda, and K. L. Molnar-Kimber (2000)
Clin. Cancer Res. 6, 3342-3353
   Abstract »    Full Text »
Intergeneric poliovirus recombinants for the treatment of malignant glioma.
M. Gromeier, S. Lachmann, M. R. Rosenfeld, P. H. Gutin, and E. Wimmer (2000)
PNAS 97, 6803-6808
   Abstract »    Full Text »    PDF »
Oncolysis of Diffuse Hepatocellular Carcinoma by Intravascular Administration of a Replication-competent, Genetically Engineered Herpesvirus.
T. M. Pawlik, H. Nakamura, S. S. Yoon, J. T. Mullen, S. Chandrasekhar, E. A. Chiocca, and K. K. Tanabe (2000)
Cancer Res. 60, 2790-2795
   Abstract »    Full Text »    PDF »
Complement Depletion Facilitates the Infection of Multiple Brain Tumors by an Intravascular, Replication-Conditional Herpes Simplex Virus Mutant.
K. Ikeda, H. Wakimoto, T. Ichikawa, S. Jhung, F. H. Hochberg, D. N. Louis, and E. A. Chiocca (2000)
J. Virol. 74, 4765-4775
   Abstract »    Full Text »
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation in Mice.
P. Sundaresan, W. D. Hunter, R. L. Martuza, and S. D. Rabkin (2000)
J. Virol. 74, 3832-3841
   Abstract »    Full Text »
An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma.
S. S. YOON, H. NAKAMURA, N. M. CARROLL, B. P. BODE, E. A. CHIOCCA, and K. K. TANABE (2000)
FASEB J 14, 301-311
   Abstract »    Full Text »
Inhibition of Rat Vascular Smooth Muscle Cell Proliferation In Vitro and In Vivo by Recombinant Replication-Competent Herpes Simplex Virus • Editorial Comment.
S.-I. Miyatake, H. Yukawa, H. Toda, N. Matsuoka, R. Takahashi, N. Hashimoto, and C. D. Kontos (1999)
Stroke 30 , 2431-2439
   Abstract »    Full Text »    PDF »
B-myb Promoter Retargeting of Herpes Simplex Virus gamma 34.5 Gene-Mediated Virulence toward Tumor and Cycling Cells.
R. Y. Chung, Y. Saeki, and E. A. Chiocca (1999)
J. Virol. 73, 7556-7564
   Abstract »    Full Text »
Attenuated, Replication-Competent Herpes Simplex Virus Type 1 Mutant G207: Safety Evaluation of Intracerebral Injection in Nonhuman Primates.
W. D. Hunter, R. L. Martuza, F. Feigenbaum, T. Todo, T. Mineta, T. Yazaki, M. Toda, J. T. Newsome, R. C. Platenberg, H. J. Manz, et al. (1999)
J. Virol. 73, 6319-6326
   Abstract »    Full Text »
Ionizing Radiation Improves Survival in Mice Bearing Intracranial High-Grade Gliomas Injected with Genetically Modified Herpes Simplex Virus.
J. D. Bradley, Y. Kataoka, S. Advani, S. M. Chung, R. B. Arani, G. Y. Gillespie, R. J. Whitley, J. M. Markert, B. Roizman, and R. R. Weichselbaum (1999)
Clin. Cancer Res. 5, 1517-1522
   Abstract »    Full Text »    PDF »
Use of Carrier Cells to Deliver a Replication-selective Herpes Simplex Virus-1 Mutant for the Intraperitoneal Therapy of Epithelial Ovarian Cancer.
G. Coukos, A. Makrigiannakis, E. H. Kang, D. Caparelli, I. Benjamin, L. R. Kaiser, S. C. Rubin, S. M. Albelda, and K. L. Molnar-Kimber (1999)
Clin. Cancer Res. 5, 1523-1537
   Abstract »    Full Text »    PDF »
Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors.
S. J. Advani, S.-M. Chung, S. Y. Yan, G. Y. Gillespie, J. M. Markert, R. J. Whitley, B. Roizman, and R. R. Weichselbaum (1999)
Cancer Res. 59, 2055-2058
   Abstract »    Full Text »    PDF »
Intracerebral Adenovirus-mediated p53 Tumor Suppressor Gene Therapy for Experimental Human Glioma.
H. Li, M. Alonso-Vanegas, M. A. Colicos, S. S. Jung, H. Lochmuller, A. F. Sadikot, G. J. Snipes, P. Seth, G. Karpati, and J. Nalbantoglu (1999)
Clin. Cancer Res. 5, 637-642
   Abstract »    Full Text »    PDF »
THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif..
J. H. Sampson (1999)
Neuro-oncol 1, 33-42
   PDF »
Interleukin-6 Modulated Conditionally Replicative Adenovirus as an Antitumor/Cytotoxic Agent for Cancer Therapy.
C. Rancourt, A. Piche, J. Gomez-Navarro, M. Wang, R. D. Alvarez, G. P. Siegal, G. M. Fuller, S. A. Jones, and D. T. Curiel (1999)
Clin. Cancer Res. 5, 43-50
   Abstract »    Full Text »    PDF »
Topical Review: Gene Therapy for Neurologic Disease: Benchtop Discoveries to Bedside Applications. 1. The Bench.
B. L. Maria, C. D. Medina, K. B.N. Hoang, and M. I. Phillips (1997)
J Child Neurol 12, 1-12
   Abstract »    PDF »
Cerebral microenvironment influences expression of the vitronectin gene in astrocytic tumors.
C. Gladson, J. Wilcox, L Sanders, G. Gillespie, and D. Cheresh (1995)
J. Cell Sci. 108, 947-956
   Abstract »    PDF »
Neurological Surgery.
R. H. Wilkins (1994)
JAMA 271, 1684-1685
   Abstract »    PDF »
Gene Therapy for Neurologic Disease.
S. T. Suhr and F. H. Gage (1993)
Arch Neurol 50, 1252-1268
   Abstract »    PDF »
The Future of Child Neurology.
J. B. Bodensteiner, J. F. Bale Jr, and P. C. Ferry (1992)
J Child Neurol 7, 104-111
   PDF »
From the Cover: Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors.
J. N. Parker, G. Y. Gillespie, C. E. Love, S. Randall, R. J. Whitley, and J. M. Markert (2000)
PNAS 97, 2208-2213
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)